Stock market today: S&P 500 climbs as health care, tech gain; Nvidia earnings loom
BioCryst Pharmaceuticals Inc. (NASDAQ:BCRX), a company specializing in biological products with a market capitalization of $1.78 billion, announced the resignation of Chief Financial Officer Anthony Doyle. Mr. Doyle, who has been with the Durham, North Carolina-based company since April 2020, will step down from his role effective April 9, 2025. The announcement was made through a Form 8-K filing with the Securities and Exchange Commission on Monday.
During his tenure, Doyle has been credited with contributing significantly to the global launch of ORLADEYO and strengthening the company’s financial position, as evidenced by impressive 36% revenue growth to $450.71 million and a healthy current ratio of 2.63. BioCryst emphasized that his departure is not due to any disagreements on matters of operations, policies, or practices.
The company has expressed gratitude for Doyle’s dedicated service and extended well wishes for his future endeavors. To ensure a smooth transition, Doyle will continue in his current capacity until his effective resignation date. Meanwhile, BioCryst has initiated a search for a new CFO to take over the financial leadership of the organization.
This executive change comes at a time when BioCryst is approaching a critical phase of profitability, highlighting the importance of financial leadership in the company’s ongoing success. The information regarding this transition is based on the company’s recent SEC filing.
In other recent news, BioCryst Pharmaceuticals has reported a fourth-quarter 2024 revenue of $131.53 million, surpassing analyst estimates of $127.17 million and marking a 40.8% increase year-over-year. Despite exceeding revenue expectations, the company reported a larger-than-expected loss per share of $0.13, compared to the anticipated $0.07 loss. BioCryst has raised its 2025 revenue guidance for Orladeyo, projecting global net revenue between $535 million and $550 million, attributing this to increased affordability for Medicare patients under the Inflation Reduction Act. JMP Securities and H.C. Wainwright have maintained their positive ratings on BioCryst, with price targets of $18.00 and $30.00, respectively. Piper Sandler also reaffirmed an Overweight rating with a $23.00 target, highlighting BioCryst’s strategic pipeline investments and commercial potential. Analysts from Citizens JMP and Piper Sandler noted BioCryst’s updated 2025 revenue guidance, with projections ranging from $560 million to $575 million. The company is focusing on promising developments in its rare disease pipeline, including BCX17725 for Netherton syndrome. Despite the EPS miss, analysts like JPMorgan’s Jessica Fye remain optimistic, citing the upward revenue guidance as a positive indicator for the company’s growth trajectory.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.